Sign in

    John Miller

    Senior Equity Research Analyst at Evercore ISI

    Jon Miller is a Senior Equity Research Analyst at Evercore ISI focused on biotechnology and large-cap healthcare companies, where he has covered firms such as Vor Biopharma and PMV Pharmaceuticals. Over his recent performance period, Miller has made 23 stock recommendations, predominantly issuing buy ratings, with a reported success rate of 32% and an average return of -25.4% per rating according to TipRanks. He began covering stocks at Evercore ISI around 2020, and his career has centered on deep fundamental analysis in the biotech sector; however, there are no verified prior employers listed in publicly available records. Miller's professional credentials and securities licenses are not explicitly noted, but as an equity analyst at a major institution, he is expected to hold relevant FINRA registrations.

    John Miller's questions to Zymeworks (ZYME) leadership

    John Miller's questions to Zymeworks (ZYME) leadership • Q2 2025

    Question

    On behalf of John Miller from Evercore, an analyst asked about the key differentiating factors for ZW1528, questioning the relative contributions of its bispecific design versus its long half-life, and inquired about the planned dosing strategy for ZW251.

    Answer

    CSO Paul Moore explained that for ZW1528, both the bispecific targeting of IL-4/IL-33 and the half-life extension are integral design features for achieving superior efficacy. SVP of Clinical Development Sabeen Mekan stated that for ZW251, they can pursue a less conservative starting dose due to strong preclinical safety data and clinical experience with the same payload from the ZW191 program.

    Ask Fintool Equity Research AI

    John Miller's questions to MACROGENICS (MGNX) leadership

    John Miller's questions to MACROGENICS (MGNX) leadership • Q4 2023

    Question

    Asked about unseen Phase 1 data for the new Vobaduo expansion cohorts, the strategic shift to pursue these indications now, and the differentiation of the MGC-026 ADC from other Topo-1 ADCs.

    Answer

    Scott Koenig confirmed there is still unpublished Phase 1 data for other indications. The decision to expand now is based on prior interest, promising activity in other cancers, and the potential for an improved safety profile. For MGC-026, he highlighted its potential advantages, including a more potent payload (exatecan), less susceptibility to drug resistance, and a design that may reduce lung toxicity (ILD) seen with other ADCs.

    Ask Fintool Equity Research AI